FDA Approves REMS for Extended-Release, Long-Acting Opioids

The US Food and Drug Administration (FDA) has approved a new Risk Evaluation and Mitigation Strategy (REMS) for extended-release (ER) and long-acting (LA) opioid analgesics in the treatment of moderate to severe chronic pain. The centerpiece of the plan is education for prescribers. [Read more…]